This therapy identifies terrible genes in our bodies and seeks to repair them. This may show a marked increase in the life expectancy of men with advanced prostate cancer. The study was particularly interested in a particular gene mutation that occurred in the patients sampled for the study.
These mutations were then identified and treated with new drug therapy. This style of treatment has been used in treating breast, ovarian, and lung cancer. The drug called Lynparza was used, and if it worked, it would repair the damaged DNA in the cells that could potentially lead to cancer developing.
This type of therapy is best performed when the gene is not altered. Lynparza has seen a delayed progression of cancer in altered genes linked to DNA repair. Also, the pain was significantly reduced during treatment.
Lynparza is a new type of drugs in a class called PARP inhibitors, whose function is to obstruct protein needed by cancer cells to maintain healthy DNA. These cells may die without this protein. It has been proven that cancer cells with DNA-repair gene defects are especially sensitive to these inhibitors.
Prostate cancer has lagged when it comes to the development of new drugs to fight the spread of prostate cancer. Types of prostate cancer are of many kinds, and this may be the reason why a universal drug may not be the best option. Also, bear in mind that this type of treatment only works for those patients with DNA- repair gene alterations, which are most likely inherited.
It can be a tedious process to screen for these gene flaws, which are usually overlooked by doctors during screening. Until it becomes a part of the screening guidelines, there is no possible way of detecting them.
Lynparza has various side effects, such as nausea and anemia, to mention a few. This was the reason that caused cancer patients to drop out of this treatment altogether. This drug is also expensive.